share_log

HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target

Benzinga ·  Aug 9, 2023 06:30

HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment